Intellectus Partners LLC Has $910,000 Stock Position in Amgen Inc. $AMGN

Intellectus Partners LLC grew its holdings in shares of Amgen Inc. (NASDAQ:AMGN) by 226.3% in the 3rd quarter, according to its most recent disclosure with the SEC. The fund owned 3,224 shares of the medical research company’s stock after acquiring an additional 2,236 shares during the period. Intellectus Partners LLC’s holdings in Amgen were worth $910,000 as of its most recent SEC filing.

Other hedge funds also recently modified their holdings of the company. Laurel Wealth Advisors LLC increased its holdings in Amgen by 27,765.8% in the second quarter. Laurel Wealth Advisors LLC now owns 6,700,621 shares of the medical research company’s stock valued at $1,870,880,000 after purchasing an additional 6,676,575 shares during the period. Norges Bank bought a new position in Amgen during the 2nd quarter worth $1,663,726,000. Vanguard Group Inc. lifted its holdings in Amgen by 1.6% during the 2nd quarter. Vanguard Group Inc. now owns 53,711,570 shares of the medical research company’s stock worth $14,996,807,000 after buying an additional 841,117 shares during the period. Charles Schwab Investment Management Inc. lifted its holdings in Amgen by 5.6% during the 2nd quarter. Charles Schwab Investment Management Inc. now owns 12,893,677 shares of the medical research company’s stock worth $3,600,043,000 after buying an additional 687,735 shares during the period. Finally, Panagora Asset Management Inc. grew its position in shares of Amgen by 367.4% in the 2nd quarter. Panagora Asset Management Inc. now owns 490,457 shares of the medical research company’s stock valued at $136,940,000 after buying an additional 385,517 shares during the last quarter. Institutional investors and hedge funds own 76.50% of the company’s stock.

Analysts Set New Price Targets

Several brokerages have recently weighed in on AMGN. Rothschild & Co Redburn increased their price target on Amgen from $180.00 to $200.00 and gave the company a “sell” rating in a research note on Wednesday, February 18th. Guggenheim lifted their price objective on Amgen from $305.00 to $347.00 and gave the stock a “neutral” rating in a research note on Friday, February 6th. Wall Street Zen cut Amgen from a “buy” rating to a “hold” rating in a report on Saturday, February 21st. Argus increased their target price on shares of Amgen from $360.00 to $400.00 and gave the company a “buy” rating in a research report on Friday, February 6th. Finally, Mizuho raised their price target on shares of Amgen from $280.00 to $295.00 and gave the stock an “outperform” rating in a report on Tuesday, February 10th. One equities research analyst has rated the stock with a Strong Buy rating, fourteen have given a Buy rating, twelve have given a Hold rating and two have assigned a Sell rating to the stock. According to MarketBeat.com, the company has a consensus rating of “Hold” and an average target price of $354.17.

Amgen Stock Performance

Shares of Amgen stock opened at $369.53 on Friday. The business has a 50-day moving average price of $353.26 and a two-hundred day moving average price of $322.43. Amgen Inc. has a 1-year low of $261.43 and a 1-year high of $391.29. The company has a current ratio of 1.14, a quick ratio of 0.90 and a debt-to-equity ratio of 5.78. The company has a market cap of $199.20 billion, a P/E ratio of 25.97, a PEG ratio of 3.65 and a beta of 0.45.

Amgen (NASDAQ:AMGN) last announced its quarterly earnings data on Tuesday, February 3rd. The medical research company reported $5.29 earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of $4.76 by $0.53. Amgen had a return on equity of 148.37% and a net margin of 20.98%.The company had revenue of $9.87 billion for the quarter, compared to the consensus estimate of $9.46 billion. During the same period in the previous year, the business earned $5.31 EPS. The firm’s revenue was up 8.6% compared to the same quarter last year. Amgen has set its FY 2026 guidance at 21.600-23.000 EPS. As a group, analysts anticipate that Amgen Inc. will post 20.62 EPS for the current year.

Amgen Announces Dividend

The firm also recently declared a quarterly dividend, which will be paid on Friday, June 5th. Shareholders of record on Friday, May 15th will be paid a $2.52 dividend. The ex-dividend date of this dividend is Friday, May 15th. This represents a $10.08 annualized dividend and a yield of 2.7%. Amgen’s payout ratio is 70.84%.

Key Stories Impacting Amgen

Here are the key news stories impacting Amgen this week:

• Positive Sentiment: Amgen’s recent quarter beat revenue and EPS estimates and management issued FY‑2026 EPS guidance, which supports the buy thesis and helped lift sentiment. Why Is Amgen (AMGN) Up 3.6% Since Last Earnings Report?
• Positive Sentiment: The board declared a $2.52 quarterly dividend (ex‑dividend May 15), reinforcing shareholder returns and supporting income‑oriented demand for the stock. AMGEN ANNOUNCES 2026 SECOND QUARTER DIVIDEND
• Neutral Sentiment: Amgen will present at the Leerink Partners 2026 Global Healthcare Conference (Mar 11). The fireside chat with the CFO and rare‑disease head could provide more detail on pipeline priorities and capital allocation — a potential catalyst depending on the tone. AMGEN TO PRESENT AT THE LEERINK PARTNERS 2026 GLOBAL HEALTHCARE CONFERENCE
• Neutral Sentiment: Short‑interest data reported for early March appears to show no meaningful short position (entries list zeros/NaN), which suggests short sellers are not a large immediate pressure point — note the data may reflect reporting quirks.
• Negative Sentiment: Amgen and partner Kyowa Kirin halted all rocatinlimab trials after safety signals linking OX40 pathway modulation to malignancies. Losing a late‑stage immunology asset is a clear pipeline setback and could reduce upside from future launches. Amgen Faces Rocatinlimab Halt And Rethinks Pipeline And Capital Priorities
• Negative Sentiment: Senate Democrats are pressing pharma companies over pricing deals tied to the prior administration, raising the risk of increased political and regulatory scrutiny that could pressure margins or pricing for large biopharma firms including Amgen. Pharma giants pressed by Senate Democrats over Trump pricing deals
• Negative Sentiment: At least one analyst piece has downgraded the stock to a “hold” / advised waiting for a better entry point, signaling some caution on valuation after the recent run. Amgen: Wait For A Better Entry Point (Rating Downgrade)

About Amgen

Amgen Inc (NASDAQ: AMGN) is a global biotechnology company founded in 1980 and headquartered in Thousand Oaks, California. The company focuses on discovering, developing, manufacturing and delivering human therapeutics that address serious illnesses. Amgen’s work centers on biologic medicines derived from cellular and molecular biology, with an emphasis on translating advances in human genetics and protein science into therapies for patients.

Amgen’s commercial portfolio has historically included biologics used in oncology, supportive care, nephrology, bone health and cardiovascular disease.